AMYLYX PHARMACEUTICALS INC
AMLX · NASDAQ
Updated at 2026-10-14 08:31:37
- Today's High
- $27.69
- Today’s Low
- $26.80
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $28.04
- Previous Close
- $27.48
- Volume
- 1.1M
- Market Cap
- $3.44B
- P/E Ratio
- --
- EPS
- $-1.43
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Pharmaceuticals
- Sub-industry
- DRUG MANUFACTURERS - SPECIALTY & GENERIC
- Headquarters
- 55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA, UNITED STATES, 02142
- Country
- US
- Listing Date
- 2022-01-07
- Fiscal Year End
- December
- Shares Outstanding
- 111.19M
- CIK
- 0001658551
- Website
- www.amylyx.com
Amylyx Pharmaceuticals Inc (AMLX) is an innovative biopharmaceutical company at the forefront of developing transformative therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). The company's lead candidate, AMX0035, employs a unique neuroprotective mechanism that has shown significant potential in improving patient outcomes in clinical trials. With a robust pipeline and a dedicated team of neurology experts, Amylyx is well-positioned to tackle substantial unmet medical needs in the neurodegenerative space, making it an attractive investment opportunity for institutional investors seeking to support advancements in critical healthcare solutions.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-12-31
$0
2025-09-30
$0
Operating Expenses
2026-06-30
$45.69M
2026-03-31
$43.77M
2025-12-31
$36.49M
2025-09-30
$16.17M
Net Income
2026-06-30
-$43.42M
2026-03-31
-$41.28M
2025-12-31
-$32.99M
2025-09-30
-$34.38M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
Earnings Per Share
2026-06-30
$-0.39
2026-03-31
$-0.37
2025-12-31
$-0.30
2025-09-30
$-0.37
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$43.38M
2026-03-31
-$41.18M
2025-12-31
-$30.94M
2025-09-30
-$34.26M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
-0.13%
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Expenses | $45.69M | $43.77M | $36.49M | $16.17M |
| Net Income | -$43.42M | -$41.28M | -$32.99M | -$34.38M |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $-0.39 | $-0.37 | $-0.30 | $-0.37 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$43.38M | -$41.18M | -$30.94M | -$34.26M |
| Effective Tax Rate | -- | -- | -0.13% | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.